Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lotemax Gel 0.38% for inflammation and pain after cataract surgery
NCT02208297Phase 3Completed
- Sponsor
- Bausch + Lomb
- Start
- Sep 2014
- Primary completion
- Mar 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of loteprednol etabonate ophthalmic gel 0.38% in ocular inflammation, pain, sponsored by Bausch + Lomb. Started Sep 2014; status: completed.
02
Drugs
loteprednol etabonate ophthalmic gel 0.38%
03
Conditions
ocular inflammationpain
Beyond the preview
Go deeper on NCT02208297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02208297.